Welcome to our dedicated page for TAKEDA PHARMACEUTICAL CO SEC filings (Ticker: TAK), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on TAKEDA PHARMACEUTICAL CO's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into TAKEDA PHARMACEUTICAL CO's regulatory disclosures and financial reporting.
Smoter Jennifer Marie reported acquisition or exercise transactions in this Form 4 filing.
Takeda Pharmaceutical reported that Chief Communications & Government Officer Jennifer Marie Smoter received an equity award in the form of 18,808 American Depositary Shares through a grant of restricted stock units (RSUs). Each RSU represents a contingent right to receive one ADS at no purchase price.
The RSUs vest in three equal annual installments beginning on July 1, 2027, tying the full value of the award to continued service and future vesting dates. Following this award, Smoter is shown as directly holding 18,808 ADS, reflecting a compensation-related equity grant rather than any open‑market share purchase or sale.
Ibrahim Ramy Riad Ahmed reported acquisition or exercise transactions in this Form 4 filing.
TAKEDA PHARMACEUTICAL CO LTD reported that President, PDT BU, Ramy Riad Ahmed received a grant of 25,078 American Depositary Share-based restricted stock units as equity compensation. The award was granted at no cash cost to him and increases his direct holdings to 109,865 American Depositary Shares.
The restricted stock units vest in three equal annual installments beginning on July 1, 2027, meaning the executive earns one-third of the shares each year over a three-year period, as long as the vesting conditions are met.
Greenway Nicola Deidre Petal reported acquisition or exercise transactions in this Form 4 filing.
Takeda Pharmaceutical reported that Chief Human Resources Officer Nicola Deidre Petal Greenway received an equity award of 22,570 American Depositary Shares in the form of restricted stock units (RSUs). The units were granted at no cash cost to her as compensation.
Each RSU represents a contingent right to one American Depositary Share and will vest in three equal annual installments beginning on July 1, 2027. After this award, Greenway directly holds 94,406 American Depositary Shares, highlighting a meaningful ongoing equity stake that ties her compensation to Takeda’s long-term performance.
Farajallah Awny Samaan Botros reported acquisition or exercise transactions in this Form 4 filing.
Takeda Pharmaceutical Chief Medical Officer Awny Samaan Farajallah received an equity grant of 17,554 American Depositary Shares as a compensation award. The award is in the form of restricted stock units, each convertible into one ADS, and vests in three equal annual installments starting on July 1, 2027. Following this grant, his direct holdings increase to 130,183 ADSs, reinforcing equity-based alignment with shareholders through a long-term vesting schedule.
Furney Natalie Anne Marie reported acquisition or exercise transactions in this Form 4 filing.
Takeda Pharmaceutical’s Global General Counsel Natalie Anne Marie Furney received a compensation-related equity grant. She was awarded 43,886 American Depositary Shares on a grant basis at no cash price, increasing her direct holdings to 235,166 ADSs.
The award is structured as restricted stock units, with each RSU representing one ADS. These RSUs vest in three equal annual installments beginning on July 1, 2027, meaning the shares are delivered over time as long-term incentive compensation rather than all at once.
Pacheco Rhonda Janice reported acquisition or exercise transactions in this Form 4 filing.
Takeda Pharmaceutical President, U.S. Business Unit, Rhonda Janice Pacheco received an equity grant of 50,156 restricted stock units, each representing one American Depositary Share. The award was granted at no cash cost to her as compensation rather than an open-market purchase.
The RSUs vest in three equal annual installments beginning on July 1, 2027, meaning she earns the shares over time if service conditions are met. Following this grant, she directly holds 199,408 American Depositary Shares, aligning a larger portion of her compensation with Takeda’s long-term performance.
Pignagnoli Agosti Marcello reported acquisition or exercise transactions in this Form 4 filing.
TAKEDA PHARMACEUTICAL CO LTD reported that officer Marcello Pignagnoli Agosti received an equity award in the form of 27,586 American Depositary Shares through restricted stock units. This award was granted at no cash cost to him and increases his directly held stake to 199,934 ADS.
The restricted stock units vest in three equal annual installments beginning on July 1, 2027, meaning the shares will be delivered over time as long-term compensation. This is a routine, compensation-related grant rather than an open-market purchase or sale.
Ricci Gabriele reported acquisition or exercise transactions in this Form 4 filing.
Takeda Pharmaceutical’s Chief Data & Technology Officer Gabriele Ricci received an equity award of 37,616 American Depositary Shares through restricted stock units. The RSUs were granted at no cash cost and vest in three equal annual installments beginning on July 1, 2027.
Each RSU represents a contingent right to receive one American Depositary Share of Takeda Pharmaceutical Co. Ltd. Following this compensation-related grant, Ricci directly holds 196,742 American Depositary Shares, highlighting a meaningful ongoing equity stake aligned with the company’s long-term performance.
Shannon Elaine Mary reported acquisition or exercise transactions in this Form 4 filing.
Takeda Pharmaceutical executive Shannon Elaine Mary, President of Global Supply & Quality, received an award of 30,094 American Depositary Shares in the form of restricted stock units. This is a compensation-related grant at a stated price of $0.00 per share, not an open‑market purchase.
Each RSU represents a contingent right to receive one American Depositary Share and will vest in three equal annual installments beginning on July 1, 2027. Following this award, Mary holds 87,674 American Depositary Shares directly, showing a larger equity stake tied to long-term performance and retention.
Duprey Lauren Rusckowski reported acquisition or exercise transactions in this Form 4 filing.
Takeda Pharmaceutical granted Chief Transformation Officer Lauren Rusckowski Duprey an award of 45,140 restricted stock units, each representing one American Depositary Share, at no cash price. The RSUs vest in three equal annual installments beginning on July 1, 2027. Following this equity award, she directly holds 273,643 American Depositary Shares.